



Healthcare Industry Partners' Framework 2022

Patient engagement and co-creation in innovation, access, governance, and equity

Background

Our health systems are now finding their feet after experiencing a once in a lifetime global health emergency that has had a great levelling effect. The COVID-19 pandemic has revealed great fault lines in all our healthcare ecosystems.

IAPO and its members now face an even greater challenge as rapid and chaotic post-pandemic healthcare ecosystem recovery programmes are being triggered globally. To catch up with the backlog of disrupted essential and critical healthcare, our health systems are in danger of collapsing once more from the old and new caseload of screening, diagnosis, treatment, and rehabilitation services, and in the meeting of the rising Long-COVID19 caseload.

The need for patient engagement and co-creation is critical now as we try to build back a better and fairer universal health coverage 2030, whilst ensuring that patient centred healthcare is not undermined in the recovery phases. We aim to keep our health systems safe, accessible, acceptable, affordable, and non-discriminatory, delivering quality healthcare throughout the build back better phases.

One thing is certain in this new reality. We all realise that we need the insight and engagement of all stakeholders to create an enabling environment for health innovation. During the Moon Shot that was the race to find effective COVID19 vaccines, all stakeholders had to join hands with patients to find innovative health technologies and improve related health literacy, access and counteract the Syndemics.

Going forward 2022-2024, IAPO is advocating the need to invest in new robust partnerships with the whole of government, whole of society and whole of the pharmaceutical industry. In this new health ecosystem the whole of the patient movement must develop new insights and skills in how to engage and co-create with regulators, health technology assessment bodies and the payers (national health insurance bodies or others) to build back better and fairer pandemic prepared patient centred One Health for all.

2022 Healthcare Industry Partners Framework

IAPO's 2022 Healthcare Industry Partners Framework (HIPF 2022) harnesses the new high-level momentum in building multistakeholder and cross sector collaborative partnerships in global healthcare.

Our HIPF 2022 envisages a new partnership arrangement in patient advocacy that engages the whole of government, whole of pharmaceutical industry, whole of regulatory authorities and the whole of the patient movement to build back better and fairer pandemic prepared patient centred One Health for all.

This HIPF 2022 is now increasing the dialogue between patients, industry stakeholders and society on the emergence of new issues of importance, like genomic medicine and Big Data bioinformatics, and ensures each other's views are heard and acknowledged. We want to work at cocreating effective solutions with our partners to meet these challenges. The HIPF 2022 enables us to discuss these issues in a timely, appropriate, and effective manner.

Our partners will now have new opportunities to work with IAPO and our member patients' organizations at a global, regional, and even national levels on a variety of issues relevant both to themselves and to patients. We now have several Memorandum of Understanding with key academic institutions and have a joint venture with the [IAPO Patients for Patient Safety](#)

[Observatory \(IAPO P4PS Observatory\)](#) in Geneva to carry forward our activity in addressing the WHO Global Patient Safety Action Plan 2030 and in addressing the antimicrobial resistance challenge through our [AMR Patients Alliance](#).

Further, IAPO is setting up the *IAPO Academy*, having tested out Moodle and other delivery platforms with *Patient Academy for Innovation and Research (PAIR)* to take forward our capacity building activity in low- and middle-income countries, starting with the Asia Pacific Region. IAPO has also set up the *African Medicines Agency Treaty Alliance (AMATA)* to address the issues of patient engagement and cocreation in African medicines regulatory affairs.

ACTIVITIES TO BE UNDERTAKEN IN 2022

1. EMPOWERMENT

- Personalized Cancer Care Alliance- Development and empowerment of WHO Eastern Mediterranean (MENA) patients' alliance with Al Hazar University
- Creating a Moodle Platform for Patient Education to host:
 - New Resource on Digital Health
 - New Health Technology Assessment and Value Based Healthcare Resource (EUNetHTA collaboration)
 - New Personalised Cancer Care/ Precision Oncology Resources and Briefings on Cancer Vaccines
 - New Biosimilars Toolkit
 - New Gene and Cell Therapy Tool Kit
 - Global Patient Safety Action Plan (Duke NUS Singapore Resources)
- Develop WHO Global Patients Safety Action Plan (Duke NUS Singapore) Patient and family engagement briefing resources and capacity building events
- Webinars:
 - 6 Webinars on Personalised Cancer Care
 - 4 Webinars on Biosimilars
 - 2 Webinars on Global Patient Safety Action Plan

2. IAPO Academy

- In 2022 IAPO is bringing all its resources and social media channels, especially YouTube and Vimeo, under one portal driven through Moodle (the world's leading education software platform used by leading medical and nursing colleges, and public health schools)

3. EMPOWERMENT THROUGH IAPO CAPACITY BUILDING EVENTS

- Latin American Patients Congress Virtual Argentina June 2022
- Global Patients Congress UAE September 2022
- 4th Asia Pacific Patients Congress Virtual Thailand Nov 2022

4. SHAPING LAW, POLICY, STANDARDS

- Forming and supporting the African Medicines Agency Treaty Alliance (African AMATA) and securing it a seat at the African Union and African Medicines Agency
- Health Technology Assessment (Duke NUS Singapore) develop our research findings to policy documents and patient education courses

- Value Based Healthcare- Collaborate with Texas University and Prof Elizabeth Teisberg and pursue this work already conducted with [Global Centre for Person Centred Value-Based Healthcare](#)
- Collaborate with The Global Coalition for Circulatory Health on NCD
- Collaborate with the NCD Alliance

5. INSTITUTIONAL ENGAGEMENT ON LAW, POLICY AND STANDARDS

- WHO:
 - Engage on the Global Patient Safety Action Plan and the World Patients Safety Day 2022
 - Participate in the World Health Assembly and make the appropriate interventions
 - Participate in the Regional WHO Committee meetings in Africa, Eastern Mediterranean, Europe, Pan American (PAHO/WHO) Southeast Asia, and Western Pacific
- Asia Pacific Economic Cooperation- Engage and collaborate with APEC Health on all health and patient initiatives
- World Bank-Continue work with WB on UHC 2030
- EUnetHTA and INAHTA collaborate developing new patient engagement in HTA frameworks

6. DRIVE RESEARCH AND CO-CREATE EVIDENCE BASE

- Duke NUS Singapore and IAPO will continue its collaboration putting research into practice and practice back into research on HTA
- Duke NUS Singapore in Asia Pacific: Global Patients Safety Action Plan 2021-30
- Al Hazar University Cairo Egypt and IAPO will continue collaboration on African Medicines Agency engagement of expert patient researchers
- Continue research collaboration with IMI Prefer on engaging HTA and Regulatory Bodies on incorporating patient preferences into value-based health care consideration and in HTA and Medicines Licencing
- Continue research collaboration with Get Real Institution on engaging HTA and Regulatory Bodies on incorporating real world data into value-based health care consideration and in HTA and Medicines Licencing

Part One - Introducing IAPO

A global voice for patients

IAPO has come of age and is the only over 21-year-old global patients alliance representing patients across all disease areas and promoting patient-centred healthcare around the world. Our Full Members are patients' organizations working at the international, regional, national, and local levels to represent and support patients, their families, and carers. Our Associate Members are other health-related, non-profit organizations working towards patient-centred healthcare.

IAPO has also introduced a new membership category in 2021: Affiliated Member. This gives patient groups who are members of an alliance member an opportunity to engage in our activity and programmes in their own rights, in addition to their activity with the parent alliance.

IAPO has nearly 300 direct members, and over 400 affiliated members, representing over 50 disease areas and in over 70 countries, and our network represents an estimated over 1 million patients directly through its member alliances.

The impact of IAPO's voice is created by the diversity and breadth of our members which incorporates the views of international and umbrella disease associations with those of community-based, self-help groups. IAPO advocates on a wide range of global health policy areas. With COVID-19 and its aftermath, we are now increasing engagement in public health policy and mental health policy. We are strengthening our engagement in healthcare financing, Health Technology Assessment and UHC 2030. Our core policy engagement remains in ensuring the delivery of safe and quality healthcare, which is accessible and with health equity.

We continue to pursue our engagement in health system strengthening and policies aimed at creating an enabling environment so that patients' organisations committed to patient-centred healthcare can engage in cocreation across the entire health system.

Our vision is to see patient-centred health care established in all countries. This means the establishment of patient-centred universal health coverage (UHC) in which patients do not suffering financial hardship in all 194 United Nations Member States (MS) by 2030.

Our Objectives In order to establish patient centred universal health coverage across the whole spectrum of healthcare from promotive, preventive, curative, rehabilitative and palliative healthcare services we want the establishment of:

- Safe Healthcare
- Quality Healthcare
- Accessible Healthcare. Access is across four areas.
 - Non-Discriminatory Healthcare
 - Physically Accessible Healthcare
 - Information Accessibility
 - Affordable Healthcare

- Acceptable Healthcare: Culturally Competent and Patient Centred (Broader Definition)

Our strategy is to:

- **EMPOWER** -Empower members with cutting edge knowledge and advocacy skills to enhance the reach, efficacy, and impact of our membership and the global patient movement in bringing about healthcare that is PC, PP and a UHC
- **DRIVE RESEARCH** -Co-create evidence based in support of healthcare that is PC, PP and a UHC and strengthen patient involvement in clinical research and global health institutes.
- **SHAPE LAW, POLICY, STANDARDS-** Apply the empowered patient community and evidence base created to shape the institutional, law, policy, practice, and standards framework for about healthcare that is PC, PP and a UHC at global, regional, and national levels.

IAPO delivers its mission and strategy globally through:

- Engaging with relevant and representative patient organisations and forming active partnerships and impact through capacity building
- Developing effective and enduring partnerships with global health institutional stakeholders and medicines regulatory authorities
- Developing innovative, timely and relevant policy and practice guidelines for patients and health policy makers
- Amplifying our message through relevant patrons (policy elite and high-level global health personalities) and publics (teachers, nurses, doctors, and medical students)
- Developing effective promotional mix that matches message, messenger and medium like websites, social media, conferences, WHO side-events, and resources.
- Advocating with one strong patient voice on relevant aspects of healthcare policy, with the aim to influence global, regional and national health agendas.

Highlights of IAPO Activity in 2021

IAPO's full list of activities in 2021 have been listed in the link below.

[https://www.iapo.org.uk/sites/default/files/files/IAPO_2021%20Highlights\(2\).pdf](https://www.iapo.org.uk/sites/default/files/files/IAPO_2021%20Highlights(2).pdf)

Additionally, all our activities can be followed on our Facebook

<https://www.facebook.com/IAPOvoice/> and on our Twitter account @IAPOvoice.

Part Two - Introducing the 2022 Healthcare Industry Partners Framework

A framework for collaboration to build back better.

IAPO's Industry Partners comprise companies, foundations and associations who commit to providing us with various levels of financial and in-kind support in exchange for relevant and appropriate benefits and entitlements. The HIPF 2022 provides a clear framework which allows IAPO and our industry stakeholders to interact and collaborate in cocreation a transparent, accountable, and highly effective way.

The importance of core support through partnership

IAPO has remained a streamlined and efficient small organization with four permanent staff members and two consultants. With COVID-19 build back better, core funding has become extremely important for IAPO.

Core funding will enable us to participate in important international policy activities in the global health governance arena such as our work with the WHO and collaboration with other global alliances with whom we have a Memorandum of Understanding in the development of policy statements. This activity would not be appropriate for external supporters to fund directly.

Resource constraints have imposed challenges on the ability of IAPO to address COVID-19 and other emerging issues as thoroughly and quickly as required in today's global political and digital environment.

Through HIPF 2022 that is well supported on a multi-year basis, IAPO can greatly enhance its ability to rapidly address complex policy issues and to undertake our core work towards patient-centred healthcare.

Defining Industry Partners

Industry Partners are companies who produce healthcare-related products or services, company-owned foundations, or the foundations and associations who represent such companies. We welcome biopharmaceutical, health devices, health informatics, health APPs and AI, digital imaging, nutraceutical, and other relevant manufacturers.

Operation

The interaction between IAPO and our Industry Partners is based on regular transparent communication. Each Partner is entitled to nominate one individual to be their Representative. This person receives a dedicated monthly Newsletter from IAPO to ensure they are kept informed about our activities and receive priority notifications as appropriate.

Partner Representatives of Gold Partners are also invited to join representatives of the other Partners in a meeting with the Governing Board once or twice per year. Due to COVID19 we have suspended face to face meetings. The benefits of these meetings include exchange of information, updates on IAPO's development and activities, in-depth discussion of current and emerging issues of relevance for Partners and patients' organizations.

Objectives

Through the HIPF 2022, IAPO believes that clear and mutually beneficial relations between the patients' movement and industry stakeholders can be demonstrated. Whilst supporting IAPO's core work through annual contributions, Partners can develop meaningful and effective working relationships with both IAPO and our member patients' organizations. This facilitates dialogue and effective patient-industry relations at the local, national, regional, and international levels, so that issues of common concern to patients and the industry can be addressed, such as the issues of patient information, advertising, transparency, and adherence to therapy.

Financial Support

Core Funding

Partners commit to providing IAPO with regular financial support, which is unrestricted in nature. This support contributes to our core capacity building and policy programme costs, and increases the sustainability and diversity of our funding, allowing us to plan our activities more effectively. We strongly believe in the importance of not being dependent on one source of income; others include membership fees, publication sales, donations, in-kind support and project funding for work such as the Congresses and Briefing Papers. Partners receive priority notice of these exciting opportunities.

The three levels of core support the Partners can provide to IAPO are:

- Gold Industry Partner: \$50,000
- Silver Industry Partner: \$30,000
- Bronze Industry Partner: \$20,000

Partners are encouraged to commit to a minimum of three years in the Partners Framework, again to ensure effective financial planning and to ensure that the full benefits of partnership are realised, Partners can explore this further with IAPO.

Partners' benefits and entitlements differ depending on the level of support provided. These benefits are described in Part Three of this booklet.

A complete list of IAPO's past Industry Partners can be found at www.iapo.org.uk/healthcare-industry-partners

Project Funding

While core support allows us to address systemic and general global healthcare issues, project funding helps us address specific areas of healthcare. Some of these areas are address patient awareness and education on some innovative healthcare development (gene and cell therapies) or some projects address traditional issues of access and patient safety under new circumstance like the uptake of digital and telehealth to improve access and the WHO Resolution on Global Patient Safety Action Plan.

Some projects may be specific to some of our industry partners like immunotherapy and oncology. Here we work collaborative with two or three other partners to improve our reach and impact. Other partners may have a project with a regional focus.

Project funding is carefully planned with the industry partners and to specific budget thresholds.

In 2022 we have the following Projects to find Health Industry Partners:

IAPO Projects in 2022

Projects in innovation

IAPO is empowering patients, driving research, and shaping law, policy, practice, and standards framework to improve patient centred healthcare and open access in the following innovative health technologies:

- **Gene and Cell Therapies.** IAPO backed the RDI UN Resolution4Rare. This builds on our 2019 Gene and Cell Therapy Tool Kit launched at WHO WHA 72. We want to raise more awareness and improve advocacy to ensure gene and cell therapies become a standard part of the essential medicines list in all WHO Member State UHC 2030. The Moon Shot that was the COVID19 vaccine race has liberated many technologies that can address new therapeutic areas, and this bodes well for rare diseases
- **Personalised healthcare and precision medicine (genomic medicines).** This gives us an opportunity to leverage the focus on increasing public awareness on the biotechnology and genomic medicine engaged in the Moon Shot to find Covid19 vaccines. We want to build upon advances in immunotherapy. We start from biomarkers, early diagnosis (liquid biopsies), precision oncology, targeted therapies, and monoclonal antibodies within the remit of immunotherapies (CAR-T and BiTE etc)
- **Cancer Vaccines** IAPO is putting these new Vaccines are medicines that help the body fight disease. They can train the immune system to find and destroy harmful germs and cells. There are many vaccines that you receive throughout your life to prevent common illnesses. There are also vaccines for cancer. There are vaccines that prevent cancer and vaccines that treat cancer
- **Digital health-** Digital health is an all-encompassing approach that has a transformational impact in not only high-income countries, but also in low- and middle-income countries. For a start, digital health is needed to ensure we deliver universal health coverage in time globally. DH can improve access to health care services for all, especially for hard-to-reach communities. DH is important in delivering patient safety and quality in healthcare services and medicines. DH has a bigger reach and impact for LMICs in health literacy as it can improve knowledge and access of health workers and communities to health information. For health economics, DH promises cost savings and efficiencies in health services delivery. Lastly, when all the government and economy is

digitalised, DH can integrate with e-economy and e-social welfare and change the social, economic, and environmental determinants of health,

- **Virtual clinics and telehealth care-** This is digital health's specific application. The pandemic has ensured public acceptance of remote healthcare support and advice. Virtual clinics with e-prescription and online pharmacies has made healthcare accessible for hard-to-reach groups. This development also brings its own safety, ethical and governance issues.

- **Self-care-** Digital healthcare and virtual clinics means that a lot of healthcare has moved out from the healthcare facilities and into the patients' homes. This has important consideration for health literacy, safety, ethics, and support. With QR Code and GS1 Standards, medicines and health devices can now have better and enabling patient information, support, and after purchase services.

- **AI and Machine Learning:** IAPO is supporting artificial Intelligence, machine learning and robotics in healthcare to free up the healthcare teams from routine and operational tasks to devote more time to deal with the human element of medicine practice and patient care. AI with digital health will improve early diagnostics and pick out patterns from big data that can improve personalisation of healthcare and its effectiveness, patient safety, and experience.

- **Patient Engagement in Research and Development.** IAPO is supporting the development of national EUPATI type of structures and Patient Academies. IAPO is engaging the European Union and EMA on their improved pathways for patient engagement in medicines development, end to end. Early and through value chain patient engagement.

- **Humanising Healthcare- AI-Jazeera TV Patient Quote:** *The pandemic has robbed many health systems of their humanity.* Post pandemic, many health systems are moving from patient centred to person centred and then humanisation of healthcare. We want to build back better and fairer health systems that have equity and compassionate healthcare at their heart. For a pandemic prepared health system, the corner stone is the patient centred healthcare with its focus on the patient and his/her personal needs and preferences regarding the disease and its treatment. We then have the personalised health care (stratified healthcare) that looks at the whole patient and their social determinants of health from health literacy, promotion, prevention, treatment, rehabilitation, palliative care, and end of life (a person-centred life course approach). We then have the WHO Framework on Integrated and People Centred healthcare. This together with WHO's compassionate healthcare that looks at humanisation of care by focussing on ALL stakeholders involved in care. It humanises health system processes and structures.

- **Transparency International:** IAPO supports the work of Transparency International's Health Sector programmes to improve information, accountability, and patient and citizen participation in good governance.

Projects in Good Governance

Good governance in healthcare enables patient engagement and co-production, and enhances patient safety, quality, and access. IAPO is engaging in:

- **WHO Global Patient Safety Action Plan 2021-2030:** IAPO has supported this flagship programme of the WHO from its earliest inception. 194 WHO Member States adopted this plan. The plan has is an authoritative policy instrument that now places on obligation on the State to undertake certain measures to reduce avoidable patient harm to zero. There is a 7x5 Matrix that requires all stakeholders, including patients and families, to address patient harm effectively:

<https://apps.who.int/iris/rest/bitstreams/1360307/retrieve>

- **Regulatory and HTA ecosystems** IAPO is keen on shaping the governance in the Regulatory and HTA ecosystems to ensure that patients can co-produce, through co-creation, a seamless and enabling regulatory and HTA ecosystem that ensures we get timely access to safe, quality, acceptable, accessible, and affordable innovative medicines, and health devices/products. IAPO wants to shape the regulatory and HTA pathways so that they allow patient engagement in all decision-making. As part of IMI

Prefer, IAPO are looking at how EMA and EUNetHTA are working seamlessly. IAPO is also looking at NICE UK and its guidance on how patients can work with HTA and MHRA UK. IAPO wants the role of patients be strengthened in all health technology assessment bodies and to ensure that patient preference and real-world data is used all financial modelling and decision-making.

- **Data Governance:** As health informatics, and especially bioinformatics, is central to innovation and development of precision medicine, personalised healthcare, and digital health. IAPO is focussed on ensuring that we have proportionate and a collective response to the Big Data response in current health data governance frameworks. We don't want to lose the opportunity offered by Big Data to advance innovation, personalised healthcare, precision medicine and access in our health systems by having inappropriate data protection, privacy, and other information safeguards. We can make sure our healthcare is safe, quality, acceptable, accessible and affordable, while instituting a framework respecting patient rights, privacy and human dignity, we want to see proportionate responses by the State, the regulators and the patient community.

Projects in Equity

- **Rare Diseases:** The UN Resolution on Persons Living with a Rare Disease December 2021 is the first-ever UN Resolution on "Addressing the Challenges of Persons Living with a Rare Disease and their Families." IAPO is mindful that the Moon Shot that was the race to find a vaccine has unleashed many genomic health technologies. Its important our patients have access these very early on.
- **Paediatrics** UN Convention on the Rights of the Child and other frameworks require that the health of children must be addressed through child patient centred approaches throughout the healthcare value chain. This starts with clinical research and medicines development that engages children and is not an afterthought, or worse still recommending off label use of adult medicines. Paediatrics forms a vertical and we can look at childhood diabetes, cancer, mental health and lung diseases with a special focus.
- **Women's Health:** With IAPO's Metrodora Awards in place now, it is important that we advance engagement of women patients in healthcare decision making and medicines and service development.
- **Mental Health:** As mental health is part of 5x5 NCD initiative, IAPO want to pursue this area of patient engagement as a special programme. With the prediction that mental health will become a critical issue post-pandemic, we will integrate mental health in all our programmes/

Congresses and Events

IAPO holds an annual regional congress and a biennial Global Patients Congress. The theme and agenda for these vary year to year. In addition, IAPO holds side events at the World Health assembly and other global health forums of interest and significance for patient advocacy.

Event budgets are drawn up after discussion with the funders and suppliers.

Congresses and Events Planned in 2022

- **World Health Assembly Mya 22-26 May 2022-** Joint side events in Geneva with non-State Actors and industry partners pending WHA public health notification
- **Latin American patients Congress June 2022-**Virtual
- **Global Patients Congress-Sept 2022-**In-Person in Dubai UAE
- **3rd Asia Pacific Patients Congress- November 2022-** Hybrid Thailand

Part Three - Partner Benefits and Entitlements

This section sets out the benefits and entitlements that Partners receive within the Core Funding arrangements of Health Industry Partners Framework 2022. Project and Congress benefits follow this but may be more specific and additional to these.

Transparent & Accountable Framework

Becoming a Partner provides an opportunity to work with the patients' movement at the international level in a transparent and accountable framework, with open dialogue and clear financial arrangements to ensure that the Partners' support is demonstrated, whilst IAPO's independence as a patients' organization is maintained.

Representation

Each Partner nominates one individual to represent them in their communications with IAPO to ensure there is a clear focal point for effective communications.

Involvement

Partnership ensures regular involvement and consultation on key healthcare issues. The Partner Representative from Gold Partners are entitled to attend one/two face-to-face meetings with other Partner Representatives and IAPO's Governing Board per year to plan collaborative activities, exchange views on current issues, discuss industry-patient relations, and work on developing the Partners Framework further.

Regular communication

The Partner's chosen representative (and any other contact from the company) receives a dedicated monthly email update to keep them informed of IAPO's development and policy activities and quarterly virtual updates, as requested. These updates also keep Partners up to date with the various discounted services offered to them, including website links, publications and Congress registration. Our dynamic website can also provide a useful source of reference.

Policy Framework

IAPO's policy development is directed by our Policy Framework. Policy positions are based on consultation with members and reflect only their views. But it is vital to include other stakeholders in this process; to promote multi-stakeholder debate and understanding and to consider the views, knowledge, and information that they can contribute.

Priority notice and consideration

Notice and priority consideration for upcoming partnership and sponsorship opportunities, e.g. for events, publications, grants and awards.

Involvement, attendance & acknowledgement at the Virtual Global Patients Congress

Pre-COVID-19, all Partners had the opportunity to give advice during the development of the virtual or face to face bi-annual Congress Programme to the Programme Facilitator and the **Organizing Committees.**

Partners can send delegates with exclusive "observer status", attend VIP sessions and their Partnership and support is acknowledged.

In the new virtual format, IAPO is replicating this with the virtual platforms like GPC2021 V-Fairs congress and other planning sessions.

Free Digital copies of IAPO's publications

The Partner is entitled to receive free copies of IAPO's digital publications, such as our Briefing Papers (upon request to info@iapo.org.uk).

Acknowledgement online

All Industry Partners' names and levels of support are fully acknowledged on our website, with further benefits such as logos and corporate profiles depending on the Partner's level of support. The Industry Partners will also have a dedicated area of our website which explains the nature of the collaboration between IAPO and our Partners.

Acknowledgement in Healthcare Industry Partners documents

Full acknowledgement of Company name and level of support in IAPO Partner documents and publicity materials, where appropriate. All Partners will be listed with the level of support in this Industry Partners booklet.

Note that the benefits and entitlements Partners receive are dependent on the level of support they provide. Please see the Benefits Matrix on the following page to see the differences.

About other sponsorship opportunities

If you are interested in sponsoring IAPO in other ways, such as sponsoring the Global Patients Congress, Asian Pacific Patients Congress, African Patients Congress in 2021 or funding the capacity building of our members, please email the CEO at kawaldip@iapo.org.uk

CORE FUNDING BENEFITS MATRIX

Benefits to Industry Partner	Level of Support		
	Gold	Silver	Bronze
Working with the patients' movement in a transparent and accountable framework	✓	✓	✓
Representation of the Partners industry sector in IAPO's work for positive change	✓	✓	✓
Dedicated monthly email newsletter	✓	✓	✓
Attendance by the Partner Representative at 1-2 virtual meetings per year	✓	-	-
As required, quarterly Zoom with IAPO's Chief Executive Officer or Policy Manager for an update or on a topic of your choice (on request)	✓	✓	-
Priority consideration for partnership and sponsorship opportunities	✓	✓	-
Benefits at the virtual Events <ul style="list-style-type: none"> • 1 x delegate patient relations officer place • 1 x extra delegate observer place • Acknowledgement and level of support in Congress Programme • Special workshops and planning sessions 	✓	✓	✓
Free digital copies of IAPO publications (on request to info@iapo.org.uk)	✓	✓	✓
Acknowledgement on IAPO website: <ul style="list-style-type: none"> • Company name and level of support listed • Link to Corporate Website • Partner Profile (summarizing the Partner's mission, work and involvement with IAPO) 	✓	✓	✓
	✓	✓	✓
<ul style="list-style-type: none"> • Partner Profile (summarizing the Partner's mission, work and involvement with IAPO) 	✓ 600 words	✓300 words	✓100 words
Acknowledgement of support in end of year newsletter	✓	✓	✓
Acknowledgement in Industry Partners Booklet:			
<ul style="list-style-type: none"> • Company name and level of support listed 	✓	✓	✓
<ul style="list-style-type: none"> • Corporate Logo 	✓	✓	-

Part Four - Becoming an Industry Partner

Application

For further information, please contact our CEO +447443101055 and we will arrange a meeting in a convenient location to discuss potential Partnership further.

Letter of Agreement

IAPO enters into partnerships with organizations upon signature of a Letter of Agreement outlining the terms of partnership by representatives of both IAPO and the partner organization.

Contact Details – IAPO Office

International Alliance of Patients' Organizations
49-51 East Road
London, N1 6AH
United Kingdom

Telephone: +44 20 7250 8280

COVID-19 Office: +447443101055

Fax: +44 20 7250 8285

Email: info@iapo.org.uk

Website: www.iapo.org.uk

Governing Board Members

IAPO's 2021 Board Members are listed below. Please contact the IAPO office for their contact details.

Dr. Ratna Devi IAPO Chair CEO and Co-founder of Dakshama Health and Education, India. Board Chair of Indian Alliance of Patient Groups and is a Partner at Prism Consulting Group.

Dr. Neda Milevska-Kostova IAPO Vice Chair Executive director of Centre for Regional Policy Research and Cooperation "Studiorum", think-tank working on health and wellbeing policies in South Eastern Europe

Karen Alparce-Villanueva Secretary is currently the Vice-President of the Philippine Alliance of Patient Organizations (PAPO)

Ellos Ellard Lodzeni IAPO Hon. Treasurer Patron and founder trustee of Patient and Community Welfare Foundation of Malawi

Orajitt Bumrungkulswat Board Member is the Assistant Secretary General Heart to Heart Foundation in Thailand

Bisi Bright is a Consultant Clinical Pharmacist, Lecturer and Public Health Manager. She is 1st Vice Chairman and CEO of LiveWell Initiative LWI

Liliana Tieri is the Founder and Executive Director Association for the Care of Diabetes in Argentina CUI.D.AR.

